146 related articles for article (PubMed ID: 22867998)
1. A polymorphism at the miR-502 binding site in the 3' untranslated region of the SET8 gene is associated with the risk of epithelial ovarian cancer.
Wang C; Guo Z; Wu C; Li Y; Kang S
Cancer Genet; 2012; 205(7-8):373-6. PubMed ID: 22867998
[TBL] [Abstract][Full Text] [Related]
2. A polymorphism at the miR-502 binding site in the 3'-untranslated region of the histone methyltransferase SET8 is associated with hepatocellular carcinoma outcome.
Guo Z; Wu C; Wang X; Wang C; Zhang R; Shan B
Int J Cancer; 2012 Sep; 131(6):1318-22. PubMed ID: 22095217
[TBL] [Abstract][Full Text] [Related]
3. An miR-502-binding site single-nucleotide polymorphism in the 3'-untranslated region of the SET8 gene is associated with early age of breast cancer onset.
Song F; Zheng H; Liu B; Wei S; Dai H; Zhang L; Calin GA; Hao X; Wei Q; Zhang W; Chen K
Clin Cancer Res; 2009 Oct; 15(19):6292-300. PubMed ID: 19789321
[TBL] [Abstract][Full Text] [Related]
4. [Polymorphism at the miR-502 binding site in the 3' untranslated region of SET8 gene is associated with the risk of clear cell renal cell carcinoma].
Xu JS; Bai YL; Zhang JX; Cui LW; Zhang HR; Zhang SL
Zhonghua Zhong Liu Za Zhi; 2016 Jun; 38(6):476-80. PubMed ID: 27346408
[TBL] [Abstract][Full Text] [Related]
5. [SNP rs16917496 within SET8 3'UTR is associated with the age of onset of breast cancer].
Zhang BL; Song FJ; Zheng H; Zhang LN; Zhao YR; Chen KX
Zhonghua Zhong Liu Za Zhi; 2012 Nov; 34(11):835-7. PubMed ID: 23291132
[TBL] [Abstract][Full Text] [Related]
6. Association of a miR-502-binding site single nucleotide polymorphism in the 3'-untranslated region of SET8 and the TP53 codon 72 polymorphism with cervical cancer in the Chinese population.
Yang SD; Cai YL; Jiang P; Li W; Tang JX
Asian Pac J Cancer Prev; 2014; 15(16):6505-10. PubMed ID: 25169478
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of microRNA 502 binding site SNP in the 3'-untranslated region of the SET8 gene in patients with non-Hodgkin's lymphoma.
Diao L; Su H; Wei G; Li T; Gao Y; Zhao G; Guo Z
Tumori; 2014; 100(5):553-8. PubMed ID: 25343552
[TBL] [Abstract][Full Text] [Related]
8. Association of miR-502-binding site single nucleotide polymorphism in the 3'-untranslated region of SET8 and TP53 codon 72 polymorphism with non-small cell lung cancer in Chinese population.
Yang S; Guo H; Wei B; Zhu S; Cai Y; Jiang P; Tang J
Acta Biochim Biophys Sin (Shanghai); 2014 Feb; 46(2):149-54. PubMed ID: 24374662
[TBL] [Abstract][Full Text] [Related]
9. A polymorphism at the miR-502 binding site in the 3' untranslated region of the SET8 gene is associated with the outcome of small-cell lung cancer.
Ding C; Li R; Peng J; Li S; Guo Z
Exp Ther Med; 2012 Apr; 3(4):689-692. PubMed ID: 22969952
[TBL] [Abstract][Full Text] [Related]
10. Association of functional polymorphism at the miR-502-binding site in the 3' untranslated region of the SETD8 gene with risk of childhood acute lymphoblastic leukemia, a preliminary report.
Hashemi M; Sheybani-Nasab M; Naderi M; Roodbari F; Taheri M
Tumour Biol; 2014 Oct; 35(10):10375-9. PubMed ID: 25048968
[TBL] [Abstract][Full Text] [Related]
11. Genetic variation in a microRNA-502 minding site in SET8 gene confers clinical outcome of non-small cell lung cancer in a Chinese population.
Xu J; Yin Z; Gao W; Liu L; Yin Y; Liu P; Shu Y
PLoS One; 2013; 8(10):e77024. PubMed ID: 24146953
[TBL] [Abstract][Full Text] [Related]
12. Functional polymorphism at the miR-502-binding site in the 3' untranslated region of the SETD8 gene increased the risk of prostate cancer in a sample of Iranian population.
Narouie B; Ziaee SAM; Basiri A; Hashemi M
Gene; 2017 Aug; 626():354-357. PubMed ID: 28578017
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of microRNA-196b Accelerates Invasiveness of Cancer Cells in Recurrent Epithelial Ovarian Cancer Through Regulation of Homeobox A9.
Chong GO; Jeon HS; Han HS; Son JW; Lee YH; Hong DG; Park HJ; Lee YS; Cho YL
Cancer Genomics Proteomics; 2017; 14(2):137-141. PubMed ID: 28387653
[TBL] [Abstract][Full Text] [Related]
14. Study of correlation between genetic variants in three microRNA genes (hsa-miR-146a, hsa-miR-502 binding site, hsa-miR-27a) and breast cancer risk.
Parchami Barjui S; Reiisi S; Ebrahimi SO; Shekari B
Curr Res Transl Med; 2017 Nov; 65(4):141-147. PubMed ID: 29128203
[TBL] [Abstract][Full Text] [Related]
15. Extensive sequence variation in the 3' untranslated region of the KRAS gene in lung and ovarian cancer cases.
Kim M; Chen X; Chin LJ; Paranjape T; Speed WC; Kidd KK; Zhao H; Weidhaas JB; Slack FJ
Cell Cycle; 2014; 13(6):1030-40. PubMed ID: 24552817
[TBL] [Abstract][Full Text] [Related]
16. miR-502 medaited histone methyltransferase SET8 expression is associated with outcome of esophageal squamous cell carcinoma.
Wang C; Wu J; Zhao Y; Guo Z
Sci Rep; 2016 Sep; 6():32921. PubMed ID: 27605386
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-145 targets TRIM2 and exerts tumor-suppressing functions in epithelial ovarian cancer.
Chen X; Dong C; Law PT; Chan MT; Su Z; Wang S; Wu WK; Xu H
Gynecol Oncol; 2015 Dec; 139(3):513-9. PubMed ID: 26472353
[TBL] [Abstract][Full Text] [Related]
18. MiR-135a functions as a tumor suppressor in epithelial ovarian cancer and regulates HOXA10 expression.
Tang W; Jiang Y; Mu X; Xu L; Cheng W; Wang X
Cell Signal; 2014 Jul; 26(7):1420-6. PubMed ID: 24607788
[TBL] [Abstract][Full Text] [Related]
19. A functional single nucleotide polymorphism of SET8 is prognostic for breast cancer.
Liu B; Zhang X; Song F; Liu Q; Dai H; Zheng H; Cui P; Zhang L; Zhang W; Chen K
Oncotarget; 2016 Jun; 7(23):34277-87. PubMed ID: 27144429
[TBL] [Abstract][Full Text] [Related]
20. The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing.
Pharoah PD; Palmieri RT; Ramus SJ; Gayther SA; Andrulis IL; Anton-Culver H; Antonenkova N; Antoniou AC; Goldgar D; ; Beattie MS; Beckmann MW; Birrer MJ; Bogdanova N; Bolton KL; Brewster W; Brooks-Wilson A; Brown R; Butzow R; Caldes T; Caligo MA; Campbell I; Chang-Claude J; Chen YA; Cook LS; Couch FJ; Cramer DW; Cunningham JM; Despierre E; Doherty JA; Dörk T; Dürst M; Eccles DM; Ekici AB; Easton D; ; Fasching PA; de Fazio A; Fenstermacher DA; Flanagan JM; Fridley BL; Friedman E; Gao B; Sinilnikova O; ; Gentry-Maharaj A; Godwin AK; Goode EL; Goodman MT; Gross J; Hansen TV; Harnett P; Rookus M; ; Heikkinen T; Hein R; Høgdall C; Høgdall E; Iversen ES; Jakubowska A; Johnatty SE; Karlan BY; Kauff ND; Kaye SB; Chenevix-Trench G; ; Kelemen LE; Kiemeney LA; Kjaer SK; Lambrechts D; Lapolla JP; Lázaro C; Le ND; Leminen A; Leunen K; Levine DA; Lu Y; Lundvall L; Macgregor S; Marees T; Massuger LF; McLaughlin JR; Menon U; Montagna M; Moysich KB; Narod SA; Nathanson KL; Nedergaard L; Ness RB; Nevanlinna H; Nickels S; Osorio A; Paul J; Pearce CL; Phelan CM; Pike MC; Radice P; Rossing MA; Schildkraut JM; Sellers TA; Singer CF; Song H; Stram DO; Sutphen R; Lindblom A; ; Terry KL; Tsai YY; van Altena AM; Vergote I; Vierkant RA; Vitonis AF; Walsh C; Wang-Gohrke S; Wappenschmidt B; Wu AH; Ziogas A; Berchuck A; Risch HA;
Clin Cancer Res; 2011 Jun; 17(11):3742-50. PubMed ID: 21385923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
